Fukunaga et al found that patients with CD8+ tumours had a higher five-year overall survival (OS) rate than patients with CD8- tumours, and similarly for patients with CD4+ tumours versus CD4- tumours [5]. The gene discussed is CD8A; the disease is neoplasm.